Peripheral Blood Progenitor Cell (PBPC) Transplantation from Haploidentical Donors Following Reduced Intensity Conditioning (RIC) for High-Risk Hematologic Malignancies
Kavita Raj(Johns Hopkins Hospital), Paul V. O’Donnell(Johns Hopkins Hospital), E. Harringon(Seattle Cancer Care Alliance), Lisa Getzendaner(Fred Hutch Cancer Center), M Kazmi(St Thomas' Hospital), Matthew Streetly(King's College - North Carolina), S.J. Lee(Seattle Cancer Care Alliance)
Cited by 9
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
|Journal of Clinical Oncology|2017|325
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
|Biology of Blood and Marrow Transplantation|2008|264